Regulatory Information
SANOFI-AVENTIS SINGAPORE PTE. LTD.
SANOFI-AVENTIS SINGAPORE PTE. LTD.
Therapeutic
Prescription Only
Formulation Information
INJECTION
**4.2 Posology and method of administration** **Posology** RESTRICTED TO ADULTS AND CHILDREN OVER 2 YEARS OF AGE. A single injection of 0.5 ml. If exposure to risk continues and depending on the level of exposure, revaccination will be performed every 2–3 years. _Paediatric population_ The vaccination schedule is the same for children and for adults. **Method of administration** Intramuscular or subcutaneous route
SUBCUTANEOUS, INTRAMUSCULAR
Medical Information
**4.1 Therapeutic indications** Prevention of typhoid fever in adults and in children over 2 years of age, and especially: travellers to endemic areas, migrants, health care professionals and military personnel.
**4.3 Contraindications** Hypersensitivity to the active substance, to any of the excipients listed in section 6.1 to formaldehyde or to casein (which may be present as traces in each dose, owing to their use during the manufacturing process) – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_. Vaccination should be postponed in case of acute febrile disease.
J07AP03
typhoid, purified polysaccharide antigen
Manufacturer Information
SANOFI-AVENTIS SINGAPORE PTE. LTD.
SANOFI PASTEUR
SANOFI WINTHROP INDUSTRIE – LE TRAIT
Active Ingredients
PURIFIED VI CAPSULAR POLYSACCHARIDE OF S.TYPHI (TYPE 2 STRAIN)
25 micrograms
Documents
Package Inserts
Typhim VI Injection PI.pdf
Approved: December 30, 2022